Post Profile






After melanoma surgery, Bristol's Opdivo offers new care standard

MADRID (Reuters) - Bristol-Myers Squibb's immunotherapy drug Opdivo is a better and safer option than its older medicine Yervoy for treating melanoma patients who have had surgery to remove disease, researchers reported on Monday.
read more

share

Related Posts


Japan sets 50 percent price cut for Bristol Myers' Opdivo cancer drug

Health : Reuters: Health

(Reuters) - Japan's health ministry has set a 50 percent cut in the price of Opdivo, a costly immune system-boosting cancer drug produced by Bristol Myers Squibb Co and marketed in the country by Ono Pharmaceutical Co Ltd, Ono Pharm...

No silver lining in failed Bristol cancer drug trial

Health : Reuters: Health

COPENHAGEN (Reuters) - Bristol-Myers Squibb disappointed investors on Sunday as researchers detailed data for its Opdivo cancer immunotherapy, which was already known to have failed to do better than older chemotherapies in a closel...

Bristol-Myers immunotherapy combination extends survival in melanoma

Health : Reuters: Health

(Reuters) - Patients with advanced melanoma who received Bristol-Myers Squibb's immunotherapies Opdivo and Yervoy had improved overall survival compared with those on Yervoy alone, with 64 percent on the combination therapy still al...

Bristol's drug cocktail cuts kidney cancer death risk 37 percent

Health : Reuters: Health

MADRID (Reuters) - A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients, data from a closely watched clinical trial showed on Sunday.

Alternative Immunotherapy Drug More Effective than Current Standard of Care in Treating Advanced Melanoma after Surgical Removal of Disease

Health : Newswise Medical News

The immunotherapy drug nivolumab is safer and more effective than ipilimumab--the current standard of care--in treating patients with resected stage III and stage IV melanoma.

Comments


Copyright © 2016 Regator, LLC